BUSINESS
One London Lab Took Most of Europe’s Healthtech Money
Isomorphic Labs’ $2.1 billion round is about 69% of Europe’s healthtech top 10 in H1 2026, a total that also folds in a loan, grants and share sales.
Isomorphic Labs raised $2.1 billion in May 2026, about 69% of the €2.59 billion collected by Europe’s ten largest healthtech financings in the first half. The London company designs drugs with AI and has not yet put one of its own candidates into a human trial.
The other nine names raised in a lower band, from €60 million to €200 million, and not all of that money was equity. A Reykjavík biosimilars loan, French public grants and secondary share sales sit on the same list as a mealtime insulin patch and a blood-draw robot.
Isomorphic Labs Took 69% of the Top 10
On May 12, 2026, Isomorphic Labs raised $2.1 billion in Series B funding led by Thrive Capital. Existing backers Alphabet and GV joined, as did new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. The company, spun out of Google DeepMind in 2021, is based in London with offices in Cambridge, Massachusetts, and Lausanne, and is run by founder and chief executive Sir Demis Hassabis and president Max Jaderberg.
Hassabis, who also leads Google DeepMind, said the new capital would scale the firm’s drug design engine, IsoDDE, and move a pipeline of programs toward the clinic. The May round was the second time the company had taken outside money. Thrive also led a $600 million first external round in March 2025, taking external capital to $2.7 billion before any of its own drugs had entered a person.
I’ve always believed the No.1 application of AI should be to improve human health.
That work started with AlphaFold, and now at @IsomorphicLabs with the mission to reimagine drug discovery and one day solve all disease!
We are turbocharging that goal with $2.1B in new funding. pic.twitter.com/Hvk20dHgjl
— Demis Hassabis (@demishassabis) May 12, 2026
The UK government’s Sovereign AI unit posted that it had invested, putting a public cheque beside two sovereign wealth names, Abu Dhabi’s MGX and Singapore’s Temasek, and beside Alphabet’s own balance sheet. Ruth Porat, president and chief investment officer of Alphabet and Google, said the lab had made “extraordinary progress in harnessing AI to accelerate drug discovery” and that the money would be used “to accelerate the work and bring important interventions to market with greater speed.”
Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential. This capital injection allows us to build out our drug design engine at scale, driving us forward in our mission to solve all disease.
Sir Demis Hassabis, Founder and CEO, Isomorphic Labs funding announcement
Jaderberg said the engine “works” and gives the company “a repeatable way to design new medicines for a wide range of diseases.” The May statement named collaborations with large drugmakers as a check on that claim. It did not name a lead molecule, a first indication with a trial date, or a valuation.
Nine Other Rounds Cannot Match That Sum
A tally of Europe’s ten largest healthtech financings in the first half of 2026 put the group at about €2.59 billion, with Isomorphic Labs at about 69%. The remaining lines are real companies with real products, and they are not in the same capital class. Galen Growth’s figures, compiled by Nelson Advisors, put European digital health at $5.9 billion in the first half across 190 deals, down from 283 a year earlier, and more than a third of that value was the Isomorphic Labs round. Take that round out and the half was essentially unchanged.
THE TEN LARGEST EUROPEAN HEALTHTECH FINANCINGS, H1 2026
| Company | Country | Amount | What closed | Date |
|---|---|---|---|---|
| Isomorphic Labs | UK | $2.1 billion | Series B equity | May 12, 2026 |
| Oviva | UK | €200 million | Series D, primary and secondary | January 22, 2026 |
| Alvotech | Iceland | $100 million | Senior term loan | December 31, 2025 |
| CeQur | Switzerland | $100 million | Series E equity | June 2026 |
| DentalMonitoring | France | €84 million | Equity investment | February 2026 |
| FineHeart | France | €83 million | €35 million Series C plus grants | January 8, 2026 |
| Ona Therapeutics | Spain | $86.6 million | Series B equity | June 4, 2026 |
| Neurent Medical | Ireland | €62.5 million | Series C equity | February 2026 |
| Vitestro | Netherlands | $70 million | Series B equity | March 10, 2026 |
| Tissium | France | €60 million | Series D2 plus EIB facility | June 2026 |
Amounts above are the figures each company announced, in the currency it used. They do not add to the ranking’s €2.59 billion because that total converts mixed dollars and euros. Even without converting, the nine smaller lines live between €60 million and €200 million, a band that would not fill a third of the Isomorphic Labs round.
More Than a Million Patients, One €200 Million Round
Oviva is the name on the list that already looks like a health system vendor rather than a bet on a model. On January 22, 2026, the company closed a €200 million Series D led by Kinnevik, with Planet First Partners, A.P. Moller Holding, Lunate, EGS Beteiligungen AG, Norrsken VC and existing investor Sofina. The round mixed new shares with secondary sales, so part of the headline paid out earlier holders rather than the P&L.
The ranking places Oviva in the UK. The company said its certified programs are reimbursed in Germany, Switzerland and the UK, and that it has supported more than one million people with lifestyle and behavioural programs. It said it reached cash-flow profitability in 2025, tripled new patient intake over two years, and will push into hypertension and type 2 diabetes. Founders Kai Eberhardt, the chief executive, and Manuel Baumann built the product as an app plus remote dietitians, psychologists and doctors, with AI used to route patients and help clinicians, not to invent a molecule.
Eberhardt said the money lets Oviva “make effective care accessible to everyone who needs it.” Christian Scherrer, senior investment director at Kinnevik, said digital care at this scale can change the cost of chronic disease for European systems that are already short of staff. More than 200 million adults in Europe live with obesity and related conditions, according to the company’s own round note, which is the demand Oviva is selling into. That is a different sale from IsoDDE.
A Loan and EU Grants Still Count as Raised
Three other lines on the top 10 are easy to misread as venture cheques. Alvotech, the Reykjavík biosimilars group listed on Nasdaq as ALVO, announced a $100 million senior term loan facility on December 31, 2025, led by GoldenTree Asset Management. The loan matures in December 2027, replaces a working-capital facility, and is available in full for the term. Chairman and chief executive Robert Wessman said it strengthens the firm’s ability to fund research and deliver biosimilars. The pipeline note at the time listed 30 products in development and four new global launches through 2026.
FineHeart, in Bordeaux and Tours, put an even more mixed package on the board. On January 8, 2026, it completed a €35 million first close of Series C and said it would receive €48 million in IPCEI Tech4Cure grants, for €83 million in all. The equity close brought in Groupe Pasteur Mutualité, Groupe Etchart and the European Innovation Council’s EIB fund, with existing holders including FH Founders. The grants, paid in tranches, are tied to FineHeart’s role as lead partner on a European active-implantable-device project. FlowMaker, its fully implantable cardiac output accelerator, sits in the left ventricle, syncs with the heartbeat, and recharges through the skin. The company said a typical implant takes about 90 minutes on a beating heart and that it is first aiming at 50,000 severe heart-failure patients a year in a market it puts at more than €5 billion.
Tissium’s €60 million June package split in half on similar lines: €30 million of Series D2 equity and a €30 million facility from the European Investment Bank, for a polymer platform that bonds tissue without sutures, including its COAPTIUM CONNECT nerve product. Oviva’s secondary sales sit in the same grey zone as those public cheques: counted in a “raised” ranking, not all of it is new equity for growth.
WHAT THE TOP 10 COUNTS THAT IS NOT A CLASSIC VENTURE ROUND
- Alvotech’s line: A two-year senior term loan from GoldenTree, not a sale of shares.
- FineHeart’s line: A €35 million Series C first close plus €48 million of non-dilutive EU grants.
- Tissium’s line: A €30 million Series D2 alongside a €30 million EIB facility.
- Oviva’s line: A Series D that the company said included secondary share sales as well as new capital.
The other mid-size names are closer to classic growth equity. CeQur closed a $100 million Series E to push CeQur Simplicity, a wearable patch for mealtime insulin, including longer wear and extra dose steps. DentalMonitoring, the Paris orthodontics software group, raised €84 million led by Lazard Elaia Capital and ISALT to expand a phone-based scan product it says already covers more than two million patients. Ona Therapeutics in Barcelona closed an oversubscribed $86.6 million Series B co-led by Columbus Venture Partners and Mérieux Equity Partners to take antibody-drug conjugates ONA-255 (breast cancer) and ONA-389 (colorectal cancer) toward the clinic. Neurent Medical in Ireland closed a €62.5 million Series C led by MVM Partners, with Sofinnova Partners, to commercialise NEUROMARK, a radiofrequency treatment for chronic rhinitis. Vitestro in Utrecht closed a $70 million oversubscribed Series B on March 10, 2026, for Aletta, a robot that draws blood using imaging and AI, with Labcorp Venture Fund, Mayo Clinic and Sutter Health among new backers as it prepares a U.S. FDA De Novo filing.
Why Has No Isomorphic Drug Reached Patients?
The concentration would read differently if IsoDDE had a drug in a person. It does not. The May statement said proceeds would go to “continued development and deployment” of the engine and to hiring in AI, engineering, drug design and clinical teams, and to moving programs “towards the clinic.” Hassabis had earlier pointed to first trials by the end of 2026, after an older aim of getting AI-designed drugs into trials by the end of 2025 had already slipped. In early November 2026, Jaderberg said the work was still preclinical and that the company was in its “first innings.”
ISOMORPHIC LABS’ OUTSIDE MONEY
- 2021: Founded in London out of Google DeepMind, with Hassabis as chief executive.
- March 2025: Closes a $600 million first external round led by Thrive Capital, with GV and Alphabet.
- May 12, 2026: Closes a $2.1 billion Series B, again led by Thrive, with Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund.
- November 4, 2026: People close to a new process describe talks on about $5 billion at about $50 billion; the round has not closed and the company has not confirmed it.
That last line is the part of the story that moved after the ranking was compiled. A $5 billion raise would be about 2.4 times the May round and would dwarf every other healthtech cheque on the European list. It would also price a company that still has not disclosed a lead molecule. The informed argument around the lab is not whether the science is fashionable. It is whether a platform can clear that gap before the next round is in the books.
WHAT WE KNOW
- Closed capital: $2.7 billion of external funding across the March 2025 and May 2026 rounds, both led by Thrive Capital.
- Clinical status: No disclosed pipeline molecule and no human trial of an Isomorphic Labs drug.
- Stated aim: Hassabis has pointed to first clinical trials by the end of 2026.
WHAT IS UNCONFIRMED
- New round: Talks described around $5 billion at about $50 billion have not closed, and Isomorphic Labs has not confirmed them.
- Valuation: The May Series B was completed at an undisclosed valuation, so any $50 billion mark is a reported talk, not a filed figure.
The May round already asked investors to pay up for software, protein models and pharma collaborations rather than for a readout in patients. Another multiple on that stack, if it lands, would make the H1 ranking look small in hindsight and would still leave the clinic as the test that has not been run.
France Built Devices While London Priced an AI Engine
Geography on the list is lopsided in a way the 69% figure already implies. Two UK names sit at the top, and one of them is larger than the rest of the sheet. Three French companies, DentalMonitoring, FineHeart and Tissium, cluster in the device and materials band. Spain, Ireland, the Netherlands, Switzerland and Iceland each appear once. The Swiss and Dutch lines, CeQur and Vitestro, are commercial device stories pulling U.S. growth money, including hospital systems on Vitestro’s round.
WHERE THE UK SAT IN H1 2026 VENTURE
- UK startups: Raised $17 billion in the first half of 2026, per Dealroom, the strongest opening half since 2022.
- Europe share: That was 39% of all European VC investment, more than the next three countries combined.
- UK AI: $12.6 billion, more than four times the $2.8 billion raised in the first half of 2025.
- Four $1 billion-plus AI rounds: Isomorphic Labs at $2.1 billion, Nscale at $2 billion, Wayve at $1.2 billion and Ineffable Intelligence at $1.1 billion.
Read that way, the healthtech crown is an AI round that happens to sit next to Nscale and Wayve. A year earlier, European healthtech as a whole pulled in €4 billion, about 12% of €33.7 billion raised across European tech, on 237 deals out of 1,923, and the ten largest healthtech deals then came to just over €2.1 billion, with Isomorphic Labs already at the top on $600 million. The 2026 top 10 is larger because one London lab came back for $2.1 billion, not because nine device and clinic companies suddenly found late-stage cheques of that size.
The UK Sovereign AI Fund’s cheque is the political tell. The unit exists to keep frontier AI firms headquartered and growing in Britain. Isomorphic Labs is the healthtech expression of that policy, and the ranking treats that policy outcome as a sector result. France’s three names are the opposite case: an orthodontic scan network, a heart implant, and a surgical polymer, each raising in the €60 million to €84 million range, two of them with public money in the stack. Those are the companies that still have to sell a procedure to a hospital.
Isomorphic Labs has not confirmed the November talks, and no date has been set for a first patient to receive one of its drugs. Until a trial starts, Europe’s healthtech league table will keep being pulled around by a single London lab that raises like a frontier AI company.
Frequently Asked Questions
Which Drugmakers Already Work With Isomorphic Labs?
Isomorphic Labs said in its May 12, 2026 funding statement that it has strategic partnerships with Novartis, Lilly and Johnson & Johnson, and that it is advancing both partnered programs and wholly owned internal programs. Those collaborations are the main public check on IsoDDE short of a human trial, and the company has not published a lead molecule against any of those names.
What Interest Rate Is Alvotech Paying on the GoldenTree Loan?
Alvotech said the $100 million senior term loan bears interest at 12.50%, payable monthly in cash, with a two-year term maturing in December 2027. The company also said it had recently placed $108 million of senior unsecured convertible bonds due 2030, and that five biosimilars are already approved and marketed, including versions of adalimumab, ustekinumab, golimumab, aflibercept and denosumab.
How Is Oviva Paid in Germany, the UK and Switzerland?
Oviva said its programs are reimbursed as a certified Digital Health Application (DiGA) in Germany, in partnership with the NHS in the UK, and as part of the Swiss healthcare system with insurers. That three-rail setup is why a digital clinic can post cash-flow profit while still raising a €200 million round that includes secondaries.
How Many Patents Protect FineHeart’s FlowMaker?
FineHeart said it holds an international portfolio of 160 patents in 27 families around FlowMaker, which it describes as fully intraventricular, wirelessly recharged, and designed to avoid an aortic bypass or a percutaneous driveline. The January 2026 package funds both clinical and industrial work on that device and FineHeart’s role as lead partner on the European AIMD project.
What Share of CeQur Simplicity Claims Run as a Pharmacy Benefit?
CeQur said better than 85% of claims for CeQur Simplicity are covered as a pharmacy benefit, with an average copay of less than $45 a month, and that nearly 90% of patients reported following their insulin regimen better with the patch than with multiple daily injections. The $100 million Series E is meant to hire more sales staff and add 7-day wear plus 1-unit and 2-unit dose options.
Disclaimer: This article is news reporting and analysis of announced funding rounds, loans and public grants. It is for information only and is not investment advice, a solicitation to buy or sell any security, or a recommendation of any private company, listed stock or fund. Anyone considering an investment in healthtech, biotechnology or related funds should consult a licensed financial adviser or other qualified professional who can review their circumstances. Figures, round sizes, valuations and clinical statuses are those given by the companies and data firms cited and may change as later rounds close or trials start.
-
BUSINESS5 months agoAramco Crash Kills 14 Two Days After Oil Restart
-
NEWS6 months agoSalah Captained Egypt to Their First World Cup Win
-
GAMING2 months agoZelda’s 40th Switch 2 Ships Without a Zelda Game
-
NEWS3 months agoApple Labor Day Deals Hide June’s Memory Price Hike
-
NEWS4 months agoEl Niño Puts Israel’s Needed Winter Rain on a Flood Clock
-
GAMING2 months agoPalworld 1.0.4 Adds Palpedia Search After the 1.0 Launch
-
NEWS4 months agoSaudi Visa Routes Split Nigerian Travelers Into Two Speeds
-
BUSINESS9 months agoBAE’s 60-Year Saudi Franchise Now Runs Through Taif
